Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

IMV Inc IMVIQ

Healthcare Biotechnology
IMV Inc. is a Canada-based company. The Company has no business operations.


GREY:IMVIQ - Post by User

IMV Inc > PT 6,- by Leeds Jones Gable
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(5)
•••
Comment by Hideawayon Apr 13, 2022 1:23pm
307 Views
Post# 34601006

RE:PT 6,- by Leeds Jones Gable

RE:PT 6,- by Leeds Jones Gableis today's trading a result of "sell on news" or are other factors at play? IMV has attempted to promote the relatively good results from the bladder cancer study by presenting at several conferences including the oral presentation at AARC. Investors do not seem impressed. Hopefully the news will take hold after Easter and we can see some movment northward.Any thoughts?
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities